In the article on lapatinib and IGF-I signaling in the February 2007 issue (1), Fig. 3 is incorrect. The corrected Fig. 3 and legend appears below. The statement that lapatinib induces expression of p27kip1 should be removed from the abstract (page 667), the Results section (page 669, 4th paragraph), and the legend for Fig. 3B.
Lapatinib inhibits EGFR and HER2 signaling in trastuzumab resistant cells. Parental, pool 2, clone 3, and clone 4 cells were treated with 1 μmol/L lapatinib for 24 h. Immunoblotting (30 μg) was done (A) for phosphorylated and total HER2 and EGFR and (B) for the downstream signaling molecules, phosphorylated and total Akt, mitogen-activated protein kinase, and S6. Actin served as a loading control. Lapatinib inhibited EGFR and HER2 phosphorylation and blocked signaling pathway downstream of these receptors in parental and resistant cells.
Footnotes
- American Association for Cancer Research
References
Volume 7, Issue 11
